Navigation Links
Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
Date:7/14/2009

NEW YORK, July 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 1 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for recurrent solid tumors in pediatric patients. This Phase 1 study is now open for enrollment at Memorial Sloan-Kettering Cancer Center in New York City. Oren Becher, MD, Instructor, Department of Pediatrics, in coordination with Eric Holland, MD, PhD, Director of the Brain Tumor group at Memorial Sloan-Kettering Cancer Center, will act as the study's Principal Investigator. The study announced today is being fully funded by an external grant provided by a private organization.

KRX-0401 is a novel, oral, anticancer agent that modulates Akt and several other important signal transduction pathways. Keryx is currently in the process of finalizing late-stage protocols for Perifosine in the treatment of Multiple Myeloma and Metastatic Colon Cancer.

STUDY RATIONALE:

Activation of the PI3K/AKT pathway has been associated with poor prognosis, or proliferation, in several pediatric tumors such as neuroblastoma, glioblastoma, rhabdomyosarcoma, and medulloblastoma. Perifosine's inhibition of this and other pathways, as well as its ability to cross the blood-brain barrier has generated much interest in exploring its potential activity in the treatment of patients with advanced brain tumors. In vitro and in vivo data presented at AACR 2009 by investigators from the National Cancer Institute demonstrated that single agent perifosine not only induced tumor regression and delayed tumor growth, but that perifosine also improved the survival of mice bearing neuroblastoma tumors. Moreover, in a Phase 2 study conducted at Memorial Sloan-Kettering Cancer Center, perifosine induced responses and delayed disease
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... S.C. , Sept. 18, 2014   3D Systems ... of the Simbionix RobotiX Mentor™ , a new robotic ... for the first time at the ERUS exhibition in ... 19 (booth #7). Robotic-assisted minimally invasive surgery represents ... demand means the needs for training for robotic surgery has ...
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 ... appointments of Dr. Ashraf Hanna , M.D., Ph.D., ... its Board of Directors. Dr. Hanna is the Vice ... and Chief Financial Officer for the Genentech Foundation, while ... Global Head of Business Development and Licensing for Roche ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... BRUNSWICK, N.J., Aug. 10, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: ... Chief Executive Officer and President of Savient will present at ... Tuesday, August 16, 2011, at 4:10 p.m. Eastern Time.  The ... New York, NY. A live webcast of ...
... 10, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) ... and development outsourcing company serving the pharmaceutical, biotechnology, and medical ... today announced its financial results for the second quarter of ... Quarterly Net Revenues Exceeded $100 Million for the First Time ...
Cached Medicine Technology:WuXi PharmaTech Announces Second Quarter 2011 Results 2WuXi PharmaTech Announces Second Quarter 2011 Results 3WuXi PharmaTech Announces Second Quarter 2011 Results 4WuXi PharmaTech Announces Second Quarter 2011 Results 5WuXi PharmaTech Announces Second Quarter 2011 Results 6WuXi PharmaTech Announces Second Quarter 2011 Results 7WuXi PharmaTech Announces Second Quarter 2011 Results 8WuXi PharmaTech Announces Second Quarter 2011 Results 9WuXi PharmaTech Announces Second Quarter 2011 Results 10WuXi PharmaTech Announces Second Quarter 2011 Results 11WuXi PharmaTech Announces Second Quarter 2011 Results 12WuXi PharmaTech Announces Second Quarter 2011 Results 13WuXi PharmaTech Announces Second Quarter 2011 Results 14WuXi PharmaTech Announces Second Quarter 2011 Results 15WuXi PharmaTech Announces Second Quarter 2011 Results 16WuXi PharmaTech Announces Second Quarter 2011 Results 17
(Date:9/18/2014)... 18, 2014 Throughout their lives, sisters ... other on, celebrate their achievements and accomplishments together, and ... and joy. , Joanie’s Sisters in Support, a support ... joined together by their battles against breast and ovarian ... which was organized in June, meets once a month ...
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. 18, 2014 (HealthDay ... therapy effectively treats normally sagging levels of the hormone in ... panel said Wednesday. The panel, from two key FDA ... drugs and require drug makers to conduct tests assessing the ... Bloomberg News . "The whole idea is to try ...
(Date:9/18/2014)... PLAINS, NY, SEPT. 18, 2014 -- Only about half ... shot each season, leaving thousands of moms-to-be and their babies ... a flu shot should be a routine part of prenatal ... officer. "Health care providers should offer their pregnant patients a ... should ask for it." , A report by the U.S. ...
(Date:9/18/2014)... 2014) -- Two independent groups of researchers led ... of Kentucky, and Charles Lowenstein, MD, of the ... the role that a gene called STXBP5 plays ... to Whiteheart, previous genome-wide association studies (GWAS) identified ... regulates a protein called Von Willebrand factor (VWF). ...
(Date:9/18/2014)... is available in German . ... strategy not to fight a pathogen tooth and nail, but rather ... One key feature of tolerance is that the disease only progresses ... carries a high pathogen load. , Roland Regoes, a senior scientist ... approach to HIV. He set about investigating whether there are infected ...
Breaking Medicine News(10 mins):Health News:Artist’s Cancer Jewelry to Benefit Joanie’s Sisters 2Health News:Artist’s Cancer Jewelry to Benefit Joanie’s Sisters 3Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:Flu vaccine for expectant moms a top priority 2Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3
... ... in Christ for A Day of Breast Health Awareness, Education and Screenings , ... Philadelphia, Pa. (Vocus) October 2, 2009 -- ... with Praise is The Cure and the Health Ministry Program will have a day-long celebration ...
... ... with chronic sinusitis and recurring sinus infections. When antibiotics fail they are left with little ... ... SinusWars LLC has been treating sinus related conditions for years and has noticed an increase ...
... "Profile America" feature from the U.S. Census Bureau: , (Logo: ... 2: FIRST GYM INSTRUCTORS , Profile America ... staying fit. Often, they have exercise equipment at home, ... But most people interested in fitness plan their busy ...
... has discovered a new way to classify stomach cancers, ... toward designing more effective treatments and improving long-term survival. ... and represents the second leading cause of cancer deaths ... from patients in Singapore, Australia and the United Kingdom ...
... 1 Two interactive computer tools released today by ... emergency planners and responders select and run alternate care ... a surge in seriously ill patients requiring acute care ... alternate care sites. , Alternate care facilities ...
... ... of hydrolysates, the performance of FBS and the consistency of a defined media. , ... Fort Collins, CO (PRWEB) October 4, ... hamster ovaries) cell line enhancement called Zap-CHO . Zap-CHO is designed to deliver superior ...
Cached Medicine News:Health News:More than 500 Breast Cancer Survivors and Community Supporters to Attend Annual 'Praise is The Cure' Event 2Health News:SinusWars LLC Launches a Successful and All Natural Alternative to Antibiotics in the Fight to Treat Chronic Sinusitis 2Health News:Duke/Singapore scientists find new way to classify gastric cancers 2Health News:New Tools Help Emergency Planners Select Alternate Care Facilities and Transfer Patients During Disasters 2Health News:InVitria Launches Zap-CHO to Enhance CHO Cell Culture Performance 2Health News:InVitria Launches Zap-CHO to Enhance CHO Cell Culture Performance 3
10 L, Racked, 96 tips/rack Extended length pipette tips recommended for 5 and 10 L pipettes....
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 ul reference mark make it ideal for low volume pipetting....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
... Diagnostics West Nile Virus IgG DxSelect ... to West Nile virus in human,serum. ... West Nile Virus,IgM Capture DxSelect, the ... symptoms of meningioencephalitis, as an aid ...
Medicine Products: